These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 17514662)

  • 41. Monitoring oral antiplatelet therapy: is it justified?
    Ang L; Mahmud E
    Ther Adv Cardiovasc Dis; 2008 Dec; 2(6):485-96. PubMed ID: 19124443
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiplatelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients.
    Gurbel PA; DiChiara J; Tantry US
    Am J Cardiol; 2007 Oct; 100(8B):18M-25M. PubMed ID: 17950828
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Importance of platelets and platelet response in acute coronary syndromes.
    Kottke-Marchant K
    Cleve Clin J Med; 2009 Apr; 76 Suppl 1():S2-7. PubMed ID: 19332590
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serglycin proteoglycan deletion in mouse platelets: physiological effects and their implications for platelet contributions to thrombosis, inflammation, atherosclerosis, and metastasis.
    Schick BP
    Prog Mol Biol Transl Sci; 2010; 93():235-87. PubMed ID: 20807648
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protease-activated receptors as targets for antiplatelet therapy.
    Hamilton JR
    Blood Rev; 2009 Mar; 23(2):61-5. PubMed ID: 18644663
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beyond hemostasis: the role of platelets in inflammation, malignancy and infection.
    McNicol A; Israels SJ
    Cardiovasc Hematol Disord Drug Targets; 2008 Jun; 8(2):99-117. PubMed ID: 18537597
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment.
    Mathewkutty S; McGuire DK
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):541-9. PubMed ID: 19419262
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo.
    Schulz C; Konrad I; Sauer S; Orschiedt L; Koellnberger M; Lorenz R; Walter U; Massberg S
    Thromb Haemost; 2008 Jan; 99(1):190-5. PubMed ID: 18217153
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monitoring platelet function to reduce the risk of ischemic and bleeding complications.
    Price MJ
    Am J Cardiol; 2009 Feb; 103(3 Suppl):35A-39A. PubMed ID: 19166711
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Facts and controversies of aspirin and clopidogrel therapy.
    Faxon DP; Freedman JE
    Am Heart J; 2009 Mar; 157(3):412-22. PubMed ID: 19249409
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prasugrel: a novel platelet ADP P2Y receptor antagonist.
    Wilson W; Gurvitch R; Ajani AE
    Cardiovasc Ther; 2009; 27(3):194-8. PubMed ID: 19689619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Platelets, cyclooxygenases, and colon cancer.
    Guillem-Llobat P; Dovizio M; Alberti S; Bruno A; Patrignani P
    Semin Oncol; 2014 Jun; 41(3):385-96. PubMed ID: 25023354
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Physiology and pathophysiology. Fundamentals of platelet pharmacology].
    Jastrow H; Weber AA
    Pharm Unserer Zeit; 2009; 38(4):302-4. PubMed ID: 19572351
    [No Abstract]   [Full Text] [Related]  

  • 54. Editor's choice articles 2006--2008.
    Preissner KT
    Thromb Haemost; 2008 Dec; 100(6):1215-7. PubMed ID: 19132257
    [No Abstract]   [Full Text] [Related]  

  • 55. Variability of response to antiplatelet therapy: what should we do next?
    Shantsila E; Lip GY
    Fundam Clin Pharmacol; 2009 Feb; 23(1):19-22. PubMed ID: 19267768
    [No Abstract]   [Full Text] [Related]  

  • 56. Platelet secretion: From haemostasis to wound healing and beyond.
    Golebiewska EM; Poole AW
    Blood Rev; 2015 May; 29(3):153-62. PubMed ID: 25468720
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modulation of platelet and leucocyte function by a Chinese herbal formulation as compared with conventional antiplatelet agents.
    Zhao L; Gaudry L; Dunkley S; Brighton T; Guo ZX; Ye ZL; Luo RZ; Chesterman CN
    Platelets; 2008 Feb; 19(1):24-31. PubMed ID: 18231935
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy.
    Christie DJ; Kottke-Marchant K; Gorman RT
    Platelets; 2008 Mar; 19(2):104-10. PubMed ID: 17852773
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiplatelet therapies for the treatment of cardiovascular disease.
    Michelson AD
    Nat Rev Drug Discov; 2010 Feb; 9(2):154-69. PubMed ID: 20118963
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Emerging insights on antiplatelet therapy. Introduction.
    Angiolillo DJ
    Am J Cardiol; 2009 Feb; 103(3 Suppl):1A-3A. PubMed ID: 19166706
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.